1.Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12. Erratum in: CA Cancer J Clin. 2021 Jul;71(4):359. doi: 10.3322/caac.21669. PMID: 33433946.
3. GBD 2017 esophageal cancer Collaborators. The global, regional, and national burden of esophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Jun;5(6):582-597.
4. Lin Y, Totsuka Y, Shan B, Wang C, Wei W, Qiao Y, et al. Esophageal cancer in high-risk areas of China: research progress and challenges. Ann Epidemiol. 2017 Mar;27(3):215-221.
5. Abnet CC, Arnold M, Wei WQ. Epidemiology of Esophageal Squamous Cell Carcinoma. Gastroenterology. 2018 Jan;154(2):360-373. doi: 10.1053/j.gastro.2017.08.023. Epub 2017 Aug 18. Erratum in: Gastroenterology. 2018 Oct;155(4):1281.
6. Dessale M, Mengistu G, Mengist HM. Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis. Int J Nanomedicine 2022;17:3735–3749.
7. Li B, Shao H, Gao L, Li H, Sheng H, Zhu L. Nano-drug codelivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review. Drug Deliv 2022;29:2130-2161.
8. Rosario R, Cui W, Anderson RA. Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies. Reprod Fertil 2022;3:R147-R162. doi: 10.1530/RAF-22-0020.
9. Kumar B, Singh S, Skvortsova I, Kumar V. Promising Targets in Anticancer Drug Development: Recent Updates. Curr Med Chem 2017;24:4729–4752.
10. Gao Y, Shen JK, Milane L, Hornicek FJ, Amiji MM, Duan Z.Targeted cancer therapy; nanotechnology approaches for overcoming drug resistance. Curr Med Chem 2015;22:1335–1347.
11. Michel C, Neubauer A, Burchert A. Molecular tumour therapy. Internist (Berl) 2015;56:1389–1400; quiz 1401–1402. doi: 10.1007/s00108-015-3817-6.
12. Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 2020;395:1078–1088.
13. de Castro Junior G, Segalla JG, de Azevedo SJ, Andrade CJ, Grabarz D, de Araújo Lima França B, et al. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced esophageal cancer: NICE trial. Eur J Cancer 2018;88:21–30.
14. Yang X, Zhai Y, Bi N, Zhang T, Deng L, Wang W, et al. Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. Chin J Cancer Res 2021;33:53–60.
15. Ruhstaller T, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild JR, Schnider A, et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, openlabel, phase III trial (SAKK 75/08). Ann Oncol 2018;29:1386–1393.
16. Rades D, Bartscht T, Hunold P, Schmidberger H, König L, Debus J, et al. Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2). Strahlenther Onkol 2020;196:795–804.
17. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, openlabel phase 3 trial. Lancet Oncol 2013;14:481–489.
18. Moehler M, Maderer A, Thuss-Patience PC, Brenner B, Meiler J,Ettrich TJ, et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol 2020;31:228–235.
19. Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A,Mansoor W, et al. Gefitinib for esophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind,placebo-controlled randomised trial. Lancet Oncol 2014;15:894–904.
20. Petty RD, Dahle-Smith A, Stevenson D, Osborne A, Massie D,Clark C, et al. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. J Clin Oncol 2017;35:2279–2287.
21. Huang J, Fan Q, Lu P, Ying J, Ma C, Liu W, et al. Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study. J Thorac Oncol 2016;11:910–917.
22. Luo H, Jiang W, Ma L, Chen P, Fang M, Ding L, et al. Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma:A Phase II Randomized Clinical Trial. JAMA Netw Open 2020;3:e2019440.
23. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L,Sawaki A, et al. Trastuzumab in combination with chemotherapyversus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697.
24. Safran HP, Winter K, Ilson DH, Wigle D, DiPetrillo T, Haddock MG, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol 2022;23:259–269. 25.Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al.Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol 2016;34:443–451.
26. Wang ZQ, Wang DS, Wang FH, Ren C, Tan Q, Li YH. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study. Invest New Drugs 2021;39:516–523.
27. Hu Z, Sun S, Zhao X, Yu H, Wu X, Wang J, et al. Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study. Oncologist 2022;27:253–e312.
28. Yanwei L, Feng H, Ren P, Yue J, Zhang W, Tang P, et al. Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study. Oncologist 2020;25:e1464-e1472.
29. Chu L, Chen Y, Liu Q, Liang F, Wang S, Liu Q, et al. A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).Oncologist 2021;26:e925–e935.
30. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized,Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol 2016;34:1448–1454.
31. Zhao J, Lei J, Yu J, Zhang C, Song X, Zhang N, et al. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. Invest New Drugs 2020;38:500–506.
32. Lu B, Lu C, Sun Z, Qu C, Chen J, Hua Z, et al. Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. J Int Med Res 2019;47:2207–2214.
33. Peng Z, Wei J, Wang F, Ying J, Deng Y, Gu K, et al. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res 2021;27:3069–3078.
34. Zhang B, Qi L, Wang X, Xu J, Liu Y, Mu L, et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun (Lond) 2020;40:711–720.
35. Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, et al. Anti-PD-1Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer:An Open-label, Dose Escalation and Expansion Study. Clin Cancer Res 2019;25:515–523.
36. Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm,open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022;7:245–253.
37. Horgan AM, Darling G, Wong R, Guindi M, Liu G, Jonker DJ, et al. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial. Dis Esophagus 2016;29:1152–1158. doi: 10.1111/dote.12444.
38. Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC,Ruessel J, Hegewisch-Becker S, et al. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer 2016;16:699.
39.Huang J, Xiao J, Fang W, Lu P, Fan Q, Shu Y, et al. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial. Cancer Med 2021;10:1681–1689.
40.Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017;18:357–370.
41. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a doubleblind, randomised phase 3 trial. Lancet Oncol 2014;15:1224–1235.
42. Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2021;6:1015–1024.
43. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R,Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre,placebo-controlled, phase 3 trial. Lancet 2014;383:31–39.
44. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28:2947–2951.
45. Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, et al. Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS One 2015;10:e0134731.
46. Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, et al. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. Eur J Cancer 2019;115:97–106.
47. Catenacci D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol 2017;18:1467–1482.
48. Shah MA, Cho JY, Tan IB, Tebbutt NC, Yen CJ, Kang A, et al. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. Oncologist 2016;21:1085–1090.
49. Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.JAMA Oncol 2017;3:620–627.
50. Pant S, Patel M, Kurkjian C, Hemphill B, Flores M, Thompson D, et al. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. Cancer Invest 2017;35:463–472.
